The Esr1 Mutations: From Bedside To Bench To Bedside

Di: Ava

本来は臨床留学への架け橋的にUniversityofTorontoの大学院(InstituteofMedicalScience)のMasterofScienceのプログラムに入りました。もともと研究には少し興味が

ESR1 Mutation: Impact on Hormone-Sensitive Disorders

Genome editing strategies for targeted correction of β-globin mutation ...

Download scientific diagram | Prevalence of cfDNA ESR1 and PIK3CA mutations in patients with metastatic breast cancer. a The sensitivity and specificity of mutation detection in cfDNA compared to 前一个B2B（bench to bedside）是指将实验室的研究成果应用到临床、转化为医药产品或者诊疗技术的过程，第二个B2B是指通过临床观察分析为基础医学研究提供思路、指导实验设计的过程，二者相辅相成，构成了转化医学的双向循环。 Acquired mutations in the ESR1 gene, which encodes for ERα, are observed in 10–50% of breast cancer metastases and are among the most common and well-studied genetic perturbations associated with ET resistance [3,4]. In particular, ESR1 genomic mutations are enriched in metastases of patients previously treated with AIs [5, 6, 7

Bedside-back-to-bench research used patient samples from a phase II clinical trial of imatinib to correlate mutations to clinical outcome and guide therapy, whereas preclinical studies conducted in GIST cell lines revealed that most mutations in the c-kit activation loop were resistant to clinically achievable doses of imatinib (101). 在转移性激素受体阳性乳腺癌中，ESR1突变是获得性耐药的常见原因，而获得性耐药是芳香化酶抑制导致的雌激素剥夺治疗的主要手段。这些突变如何影响肿瘤对现有疗法和新疗法的敏感性是研究的活跃领域。在这篇综述中，总结了现有的知识围绕ESR1突变的作用机制和芳香化酶抑制抵抗的作用，分析

Bedside-to-Bench-to-Bedside: The Keys to Successful Collaboration in Neuroscience Research May 15, 2020 The development of basic science discoveries into clinical applications – often described as “bench to bedside” work –

Bringing therapies from the bench to clinical efficacy takes effort both from the bench and from the bedside. From the bedside, detailed clinical evaluation could provide better definition of ASD features, also called endophenotypes, which can be better matched to the most representative bench models (Gottesman and Gould, 2003).

转化医学（Translational Medicine）不是单一的学科或是技术，更多地是一种转化的状态，即指从实验室到临床（bench to bedside）、从临床到实验室（bedside to bench）。转化医学具有丰富的内涵，它通过现代分子生物技术等各种方法将实验室研究成果转化为临床应用的产品与技术，同时通过临床的观察与 Hermida-Prado, F. Jeselsohn, R. Revista: Cancer Research ISSN: 1538-7445,0008-5472 Año de publicación: 2021 Volumen: 81 Número: 3 Páginas: 537-538 Tipo: Estudio Breve Exportar DOI: 10.1158/0008-5472.CAN-20-4037 GOOGLE SCHOLAR Bringing therapies from the bench to clinical efficacy takes effort both from the bench and from the bedside. From the bedside, detailed clinical evaluation could provide better definition of ASD features, also called endophenotypes, which can be better matched to the most representative bench models (Gottesman and Gould, 2003).

„from bench to bedside“の用例多数 – 単語の意味がわかる英和辞書および英語と日本語の対訳検索エンジン Hermida-Prado, F. Jeselsohn, R. Zeitschrift: Cancer Research ISSN: 1538-7445,0008-5472 Datum der Publikation: 2021 Ausgabe: 81 Nummer: 3 Seiten: 537-538 Art: Kurze Studie Exportieren DOI: 10.1158/0008-5472.CAN-20-4037 GOOGLE SCHOLAR Datenquelle: Scopus Kontakt Rechtlicher Hinweis Seitenübersicht 2021 The ESR1 Mutations: From Bedside to Bench to Bedside Cancer Research Contactar Aviso Legal translate

FRANCISCO JOSE HERMIDA PRADO

The identification, monitoring, and targeting of ESR1 mutations is an evolving field of major interest given the potential of improved outcomes in metastatic hormone receptor-positive breast cancers. Herein, the authors review the current evidence and rationale for exploiting the ESR1 mutations as a potential biomarker and therapeutic target. 允英出品｜更广范围、更高效率、更多选择，全新推出乳腺癌ESR1突变检测 -允英医疗科技有限公司是国内肿瘤精准医学的倡导者，公司致力于肿瘤个性化分子诊断的服务以及相关试剂的研发，是由一批海外归国留学人员创立的高科技企业。

This paper delves into the mechanisms and prevalence of ESR1 mutations in breast cancer, exploring their clinical implications and the role of companion diagnostics. It further highlights the essential role of robust controls in mutation detection assays to ensure precision and reliability, ultimately enhancing patient outcomes through personalized medicine. The Single-cell technologies are emerging as powerful tools for cancer research. These technologies characterize the molecular state of each cell within a tumor, enabling new exploration of tumor heterogeneity, microenvironment cell-type composition, and cell state transitions that affect therapeutic re 特集 From bedside to Bench ―臨床が基礎医学・生物学に与えたインパクト― 総説

The process is best described as a „translation continuum“ because various resources and actions are involved in this progression of knowledge, which advances discoveries from the bench to the bedside. The current model of this continuum focuses primarily on translational research, which is merely one component of the overall translation process. The phrase “bench to bedside” describes a process of taking research results from the laboratory into the clinic so that it can directly benefit bedside to bench to bedside A popular term for the repeating loop of research-based medical care, in which clinical observations stimulate research (bench), which leads back to the bedside for implementation and further clinical discovery.

Translational research: understanding the continuum from bench to bedside

Bench to Bedside: A Roadmap for Developing Novel Gene Therapies Gene therapy represents a groundbreaking approach in the field of medicine, aiming to treat or prevent diseases by modifying the genetic material within a patient’s cells. The concept involves introducing, removing, or altering genetic sequences to correct or mitigate the efects of disease-causing mutations. Over Massard, V (reprint author), Inst Cancerol Lorraine, Dept Oncol Med, F-54519 Vandoeuvre Les Nancy, France.; Merlin, JL (reprint author), Univ Lorraine, CNRS, UMR 7039

The E380Q mutation is the 3rd most prevalent identified mutation.15 Recently, most studies have focused on detecting ESR1 gene mutations in circulating tumor DNA (ctDNA) for easier sampling as an alternative to tumor tissue biop-sies.16 Several clinical studies have provided evidence that ESR1 mutations in the plasma are associated with a Furthermore, recent and ongoing studies highlight the potential clinical utility of these mutations as therapeutic targets and dynamic biomarkers. Herein, we review the structure, functional consequences, and clinical implications of the activating ESR1 mutations in advanced estrogen receptor-positive breast cancer.

“from bench to bedside”是什么意思from bench to bedside从实验室到临床双语对照例句:1.Karen tows michael to his sister’s bedside. 凯伦拉着迈克尔来到妹妹床前。

For bedside-to-bench-scoring, studies focused on basic research were excluded, as their a priori goals may not have immediate practical applications. Briefly, Bedside-to-bench-score: low (syngeneic models), moderate (ectopic CDX models), high (orthotopic CDX or GEMM), and very high (ectopic or orthotopic PDX models). Explore how ESR1 mutations influence hormone-sensitive disorders, their role in cellular disruption, and the tools used for detection and analysis.

ESR1 activating mutations: From structure to clinical application

The Bedside to Bench concept is, in many ways, the opposite of other journals, which often provide reports that go from the bench to the bedside, and I found it refreshing.

Understanding Translational Research Translational research in oncology serves as a bridge, connecting fundamental scientific discoveries from “the bench” (laboratory) with their practical application at “the bedside” (clinical care). Its core purpose is to develop new cancer treatments, diagnostic tools, and prevention strategies.

摘要：在转移性激素受体阳性乳腺癌中，ESR1突变是获得性耐药的常见原因，而获得性耐药是芳香化酶抑制导致的雌激素剥夺治疗的主要手段。这些突变如何影响肿瘤对现有疗法和新疗法的敏感性是研究的活跃领域。在这篇综述 Used to define translational research, bench-to-bedside illustrates the path by which basic science research en-deavors are transitioned from the laboratory bench to the patient ’s bedside, taking shape as a new therapy or treat-ment [1]. In our opinion, bench to bedside is inaccurate and a poor illustration of how successful translational research is conducted, especially related to

Cancer Biomarkers: Bench to Bedside Cancer Biomarkers: Bench to Bedside Oral Body Tuesday, 07 May 2024 It concludes with a discussion of the bench-to-bedside translations of these scientific discoveries as they pertain to clinicians seeing patients with these sellar tumours. Moreover, ESR1 mutations and WT ESR1 can be considered different subtypes of advanced BC with positive ERs. Future research may help better establish the use of plasma DNA sampling in clinical practice, improve our understanding of the clinical impact of the different types of ESR1 mutations, and potentially guide therapeutic selection.

QQCWB

GV